ECSP10010717A - Forma de dosificación farmaceutica para la liberación inmediata de un derivado de indolina - Google Patents

Forma de dosificación farmaceutica para la liberación inmediata de un derivado de indolina

Info

Publication number
ECSP10010717A
ECSP10010717A EC2010010717A ECSP10010717A ECSP10010717A EC SP10010717 A ECSP10010717 A EC SP10010717A EC 2010010717 A EC2010010717 A EC 2010010717A EC SP10010717 A ECSP10010717 A EC SP10010717A EC SP10010717 A ECSP10010717 A EC SP10010717A
Authority
EC
Ecuador
Prior art keywords
dosage form
pharmaceutical dosage
immediate release
indoline derivative
methyl
Prior art date
Application number
EC2010010717A
Other languages
English (en)
Inventor
Roman Messerschmid
Peter Lach
Torsten Sokoliess
Peter Stopfer
Dirk Trommeshauser
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41017080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010717(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP10010717A publication Critical patent/ECSP10010717A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B19/00—Teaching not covered by other main groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Business, Economics & Management (AREA)
  • Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Entrepreneurship & Innovation (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Educational Technology (AREA)
  • Educational Administration (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una forma de dosificación farmacéutica que suministra un perfil de liberación inmediata que contiene la sustancia activa 3-Z-[1-(4-(N-((4-metil-piperazin-1-il)-metilcarbonil)-N-metil-amino)-anilino)-1-fenil-metileno]-6-metoxicarbonil-2-indolinona-monoetanosulfonato.
EC2010010717A 2008-06-06 2010-12-23 Forma de dosificación farmaceutica para la liberación inmediata de un derivado de indolina ECSP10010717A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08157750 2008-06-06

Publications (1)

Publication Number Publication Date
ECSP10010717A true ECSP10010717A (es) 2011-02-28

Family

ID=41017080

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010717A ECSP10010717A (es) 2008-06-06 2010-12-23 Forma de dosificación farmaceutica para la liberación inmediata de un derivado de indolina

Country Status (35)

Country Link
US (3) US20110190318A1 (es)
EP (1) EP2313087B2 (es)
JP (2) JP5583119B2 (es)
KR (1) KR20110022586A (es)
CN (1) CN102056599A (es)
AR (1) AR072060A1 (es)
AU (1) AU2009254556B2 (es)
BR (1) BRPI0913235A2 (es)
CA (1) CA2726648A1 (es)
CL (1) CL2010001362A1 (es)
CO (1) CO6280468A2 (es)
CY (1) CY1121272T1 (es)
DK (1) DK2313087T4 (es)
EA (1) EA201001857A1 (es)
EC (1) ECSP10010717A (es)
ES (1) ES2711913T5 (es)
FI (1) FI2313087T4 (es)
HR (1) HRP20190181T4 (es)
HU (1) HUE042524T2 (es)
IL (1) IL209055A0 (es)
LT (1) LT2313087T (es)
MA (1) MA32386B1 (es)
MX (1) MX338001B (es)
PE (1) PE20100050A1 (es)
PL (1) PL2313087T5 (es)
PT (1) PT2313087T (es)
RS (1) RS58280B2 (es)
SG (1) SG191607A1 (es)
SI (1) SI2313087T2 (es)
TR (1) TR201901579T4 (es)
TW (1) TW201002692A (es)
UA (1) UA107560C2 (es)
UY (1) UY31876A (es)
WO (1) WO2009147220A1 (es)
ZA (1) ZA201007972B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077604A1 (en) * 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
EP2299987B1 (en) 2008-06-06 2018-02-21 Boehringer Ingelheim International GmbH Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
BR112015006363A2 (pt) 2012-09-28 2017-08-08 Boehringer Ingelheim Int combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
ES2910435T3 (es) 2013-06-04 2022-05-12 Monosol Llc Soluciones de sellado de películas solubles en agua, métodos relacionados y artículos relacionados
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
ES2971096T3 (es) 2015-06-06 2024-06-03 Cloudbreak Therapeutics Llc Composiciones y métodos para tratar el terigio
CA3026118A1 (en) 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
JP2019536812A (ja) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
WO2018177893A1 (en) 2017-03-28 2018-10-04 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of muscular dystrophy
HRP20251042T1 (hr) 2017-10-23 2025-10-24 Boehringer Ingelheim International Gmbh Nova kombinacija aktivnih sredstava za liječenje progresivnih intersticijskih bolesti pluća s fibroznim promjenama (pf-ild)
LT3761980T (lt) 2018-03-07 2024-03-12 Pliant Therapeutics, Inc. Aminorūgščių junginiai ir jų panaudojimo būdai
JP2023519600A (ja) 2020-04-01 2023-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維性状態の治療におけるバイオマーカーの使用
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3579384D1 (de) 1984-07-24 1990-10-04 Scherer Gmbh R P Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung.
DE19603402A1 (de) 1995-02-24 1996-08-29 Basf Ag Weichgelatinekapseln
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PL1948180T3 (pl) * 2005-11-11 2013-09-30 Boehringer Ingelheim Int Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
EP2299987B1 (en) * 2008-06-06 2018-02-21 Boehringer Ingelheim International GmbH Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
MY158929A (en) * 2008-06-06 2016-11-30 Boehringer Ingelheim Int Pharmaceutical combination
WO2010081817A1 (en) * 2009-01-14 2010-07-22 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
US8802384B2 (en) * 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
EP2647375A1 (en) * 2009-05-14 2013-10-09 Boehringer Ingelheim International Gmbh Combination of vargatef and dabigatran for the treatment of oncological and fibrotic diseases

Also Published As

Publication number Publication date
AR072060A1 (es) 2010-08-04
BRPI0913235A2 (pt) 2016-01-19
HRP20190181T4 (hr) 2024-07-05
DK2313087T4 (da) 2024-01-15
WO2009147220A1 (en) 2009-12-10
UA107560C2 (uk) 2015-01-26
MA32386B1 (fr) 2011-06-01
CY1121272T1 (el) 2020-05-29
US20140163040A1 (en) 2014-06-12
SG191607A1 (en) 2013-07-31
SI2313087T2 (sl) 2024-03-29
TR201901579T4 (tr) 2019-02-21
PE20100050A1 (es) 2010-01-29
CA2726648A1 (en) 2009-12-10
FI2313087T4 (fi) 2023-12-28
UY31876A (es) 2010-01-29
PT2313087T (pt) 2019-02-15
JP2014098045A (ja) 2014-05-29
CN102056599A (zh) 2011-05-11
JP5992937B2 (ja) 2016-09-14
EP2313087A1 (en) 2011-04-27
MX338001B (es) 2016-03-30
IL209055A0 (en) 2011-01-31
SI2313087T1 (sl) 2019-03-29
ES2711913T5 (es) 2024-06-24
AU2009254556B2 (en) 2015-08-20
RS58280B1 (sr) 2019-03-29
ZA201007972B (en) 2011-07-27
EP2313087B2 (en) 2023-11-22
MX2010013092A (es) 2011-02-25
AU2009254556A1 (en) 2009-12-10
CO6280468A2 (es) 2011-05-20
EP2313087B1 (en) 2018-11-21
JP5583119B2 (ja) 2014-09-03
LT2313087T (lt) 2019-02-25
US20110190318A1 (en) 2011-08-04
DK2313087T3 (en) 2019-02-18
US20130203773A1 (en) 2013-08-08
RS58280B2 (sr) 2024-02-29
ES2711913T3 (es) 2019-05-08
JP2011522010A (ja) 2011-07-28
HRP20190181T1 (hr) 2019-03-22
KR20110022586A (ko) 2011-03-07
PL2313087T3 (pl) 2019-05-31
PL2313087T5 (pl) 2024-03-04
EA201001857A1 (ru) 2011-06-30
TW201002692A (en) 2010-01-16
HUE042524T2 (hu) 2019-07-29
CL2010001362A1 (es) 2011-05-13

Similar Documents

Publication Publication Date Title
UY31876A (es) Forma de dosificación farmacéutica para la liberación inmediata de un derivado de indolinona
ECSP10010660A (es) Forma de dosificación farmacéutica en cápsula que comprende una formulación en suspención de un derivado de indolinona
DOP2012000051A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
ECSP099378A (es) Compuestos y composiciones como inhibidores de la proteina quinasa
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
SV2011004061A (es) Aril-piridinas como inhibidores de sintasa de aldosterona
UY32351A (es) Compuestos de pirimidinil indol para uso como inhibidores de atr
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
NI201400134A (es) Novedosas n - piridinil amidas cíclicas sustituidas como inhibidores de quinasa.
FR2928836B1 (fr) Forme galenique secable permettant une liberation modifiee du principe actif
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
CU20110113A7 (es) Lactamas como inhibidores beta secretasa
UY32299A (es) Composiciones farmacéuticas líquidas
EA201170843A1 (ru) Предварительно спрессованные быстро распадающиеся лекарственные формы соединений с низкой пероральной биодоступностью
TN2010000555A1 (en) Pharmaceutical dosage form for immediate release of an indolinone derivative
CU23604B7 (es) Compuestos terapéuticos
CY1114956T1 (el) Νεες συνθεσεις 1-[2-(2,4-διμεθυλο-φαινυλοσουλφανυλο)-φαινυλο]πιπεραζινης
CY1114060T1 (el) Φαρμακευτικες μορφες δοσολογιας